Reference ranges for serum prostate-specific antigen in black and white men without cancer

Urology

Volumn 52, Issue 6, 1998, Pages 967-973

  Weinrich, Martin C ^a   Jacobsen, Steven J ^c   Weinrich, Sally P ^b   Moul, Judd W ^d   Oesterling, Joseph E ^e   Jacobson, Debra ^c   Wise, Rudolph ^b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e Midwest Prostate Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CAUCASIAN; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE; RACE DIFFERENCE; REFERENCE VALUE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; REFERENCE VALUES;

EID: 0032400822     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00448-8     Document Type: Article

References (40)

1. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family a new era . Urology. 45:1995;729-744.
2. Berger N. Prostate cancer screening and early detection update . Semin Oncol Nurs. 9:1993;180-183.
3. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 330:1994;242-248.
4. Coley C.M., Barry M.J., Fleming C., et al. Early detection of prostate cancer. Part 1. Prior probability and effectiveness of tests. Ann Intern Med. 126:1997;394-406.
5. Fleming C., Wasson J., Albertsen P., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 269:1993;2650-2658.
6. Johansson J., Adami H., Andersson S., et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 267:1992;2191-2196.
7. Woolf S. Screening for prostate cancer with prostate-specific antigen. N Engl J Med. 333:1995;1401-1405.
8. American Cancer Society [97-300M-No. 5008.97]: Cancer facts & figures, 1997.
9. von Eschenbach A., Ho R., Murphy G., et al. American Cancer Society guidelines for the early detection of prostate cancer. CA Cancer J Clin. 47:1997;261-264.
10. American Urological Association: Executive Committee Report, 1992.
11. American College of Radiology: Resolution #36, 1991.
12. Regional Cancer Institute Cancer Control Objectives for the Nation: 1985-2000, 1986.
13. Guide to Clinical Preventive Services. 1996;Williams & Wilkins, Baltimore.
14. Catalona W., Richie J., Ahmann F., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men . J Urol. 151:1994;1283-1290.
15. Mettlin C., Littrup P.J., Kane R.A., et al. the Investigators of the ACS-NPCDP Relative sensitivity and specificity of serum PSA level compared to age-referenced PSA, PSA density and PSA change: data from the American Cancer Society National Prostate Cancer Detection Project . Cancer. 74:1994;1615-1620.
16. Catalona W.J., Hudson M.A., Scardino P.T., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer receiver operating characteristic curves . J Urol. 152:1994;2037-2042.
17. Brawer M.K., Chetner M.P., Beatie J., et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 147:1992;841-845.
18. Brawer M.K., Beatie J., Wener M.H., et al. Screening for prostatic carcinoma with prostate specific antigen results of the second year . J Urol. 150:1993;106-109.
19. Catalona W.J. Comparison of DRE and PSA. J Urol. 151:1994;1283-1290.
20. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
21. DeAntoni E.P., Crawford E.D., Oesterling J.E., et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 48:1996;234-238.
22. Richardson T.D., Oesterling J.E. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am. 24:1997;339-351.
23. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA. 270:1993;860-864.
24. Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med. 335:1996;304-310.
25. Jacobsen S.J., Oesterling J.E. Age-specific reference ranges for serum prostate specific antigen levels. J Clin Ligand Assay. 18:1995;93-97.
26. Crawford E.D. Prostate Cancer Awareness Week September 22-28, 1997 . CA Cancer J Clin. 47:1997;288-296.
27. Richardson T.D., Oesterling J.E. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am. 24:1997;339-351.
28. Jacobsen S.J., Bergstralh E.J., Guess H.A., et al. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. Arch Intern Med. 156:1996;2462-2468.
29. Weinrich S.P., Boyd M.D., Greene F., et al. Community sites for recruitment of African-American men into prostate cancer screening. Cancer Prac. 6:1998;23-30.
30. Weinrich SP, Atwood J, Cobb M, et al: Cost for prostate cancer educational programs and screenings in work and church sites. Am J Health Behavior Education Promotion (in press).
31. Wingo P., Bolden S., Tong T., et al. Cancer statistics for African Americans. CA Cancer J Clin. 46:1996;113-125.
32. Oesterling J.E., Jacobson S.J., Klee G.G., et al. Free, complexed and total serum prostate specific antigen the establishment of appropriate reference ranges for their concentrations and ratios . J Urol. 145:1995;1090-1095.
33. Bangma C.H., Kranse R., Blijenberg B.G., et al. The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology. 46:1995;779-784.
34. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurement. JAMA. 277:1997;1452-1455.
35. Froschermaier S.E., Pilarsky C.P., Wirth M.P. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology. 47:1996;525-528.
36. Chen Y.T., Luderer A.A., Thiel R.P., et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology. 47:1996;518-524.
37. Luderer A.A., Chen Y.T., Soriano T.F., et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 46:1995;187-194.
38. Stenman U.H., Hakama M., Knekt P., et al. Serum concentrations of prostate antigen and its complex with antichymotrypsin before diagnosis of prostate cancer. Lancet. 344:1994;1594-1598.
39. Stenman U.H., Leinonen J., Alfthan H., et al. A complex between prostate-specific antigen and antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer assay of the complex improves clinical sensitivity for cancer . Cancer Res. 51:1991;222-226.
40. Etzioni R., Shen Y., Petteway J.C., et al. Age-specific prostate-specific antigen a reassessment . Prostate. 7:(suppl):1996;70-77.